海外の治験の状況【臨床研究情報ポータルサイト】

海外の治験の状況「脳卒中」での検索結果

絞り込み

14件の検索結果

Authorised
Extending the time for thrombolytic treatment after stroke.
Acute Ischemic Stroke;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Austria, Czech Republic, Germany, Italy, Spain, United Kingdom
2013-06-11

Authorised
AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial
ischemic stroke br>MedDRA version: 9.1 Level: LLT Classification code 10061256 Term: Ischaemic stroke
Austria, Belgium, Czech Republic, Germany, Poland, Spain, Sweden
2009-02-13

Authorised
Dabigatran etexilate for Secondary Stroke Prevention in Patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown where in the body the embolus developed. MedDRA version: 18.1 Level: PT Classification code 10067167 Term: Cerebellar embolism System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10014498 Term: Embolic stroke System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10060839 Term: Embolic cerebral infarction System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10074422 Term: Brain stem embolism System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Estonia, European Union, France, Germany, Greece, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Peru, Poland, Portugal, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Thailand, United States
2014-09-05

Authorised
A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. - DIAS-3
Acute ischemic stroke within 3 - 9 hours after the onset of symptoms. MedDRA version: 14.1 Level: LLT Classification code 10055221 Term: Ischemic stroke System Organ Class: 100000004852
Austria, Estonia, France, Germany, Hungary, Netherlands, Spain
2008-10-20

Authorised
Study to find out whether “Evacetrapib” can help patients who suffer from blockages in the blood vessels to their heart, brain, or legs who are at high risk for having a heart attack, stroke or may even die from the disease
High Risk Vascular Disease (HRVD) MedDRA version: 18.1 Level: LLT Classification code 10067825 Term: Peripheral arterial disease System Organ Class: 100000004866 MedDRA version: 18.1 Level: PT Classification code 10051592 Term: Acute coronary syndrome System Organ Class: 10007541 - Cardiac disorders MedDRA version: 18.1 Level: PT Classification code 10011078 Term: Coronary artery disease System Organ Class: 10007541 - Cardiac disorders MedDRA version: 18.1 Level: LLT Classification code 10003602 Term: Atherosclerosis cerebral System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Democratic People's Republic of, Lithuania, Mexico, Netherlands, New Zealand, Peru, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
2012-07-17

Authorised
A randomised controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion.
To demonstrate the efficacy of using TNK-tPA (tenecteplase), a thrombolytic agent that is relatively novel to the treatment ischemic stroke but well-established in the treatment of myocardial infarction, to treat minor ischemic stroke patients with proven acute symptomatic occlusions or perfusion abnormalities. ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Australia, Austria, Canada, Ireland, New Zealand, Spain, United Kingdom
2016-08-08

Authorised
Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Patients with a history of acute stroke due to Intracranial Haemorrhage with mild to moderately high blood pressure. MedDRA version: 20.1 Level: PT Classification code 10019016 Term: Haemorrhagic stroke System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Australia, Brazil, Canada, China, India, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Pakistan, Philippines, Sri Lanka, Taiwan, United Kingdom, Vietnam
2018-05-15

Authorised
A Study Comparing Cardiovascular Effects of Ticagrelor versus Placebo in Patients with Type 2 Diabetes Mellitus
major cardiovascular events in type 2 diabetes mellitus patients MedDRA version: 19.1 Level: LLT Classification code 10042244 Term: Stroke System Organ Class: 100000004852 MedDRA version: 19.1 Level: PT Classification code 10028596 Term: Myocardial infarction System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russian Federation, Saudi Arabia, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
2013-11-27

Authorised
RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge translation intervention on patient outcomes - RELY-ABLE
This is a study of the long term safety of dabigatran (intended indication: stroke prevention in patients with atrial fibrillation).Eligible patients received dabigatran during the RE-LY trial 1160.26.At the time of entry into RE-LY, patients had at least one risk factor for stroke (1) congestive heart failure, 2) left ventricular dysfunction, 3) age >75, 4) age >65 years with hypertension, diabetes or coronary artery disease or 5) previous stroke, systemic embolism or transient ischemic attack) MedDRA version: 9.1 Level: LLT Classification code 10003658 Term: Atrial fibrillation
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Sweden, United Kingdom
2008-09-25

進捗状況

実施責任機関の所在地